CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last

CONMED Corporation CNMD shares have gained 16% in the past month, putting the durability of the move in focus. The rally follows better underlying growth, improved profitability and a higher earnings outlook.

Investors still have reasons to stay measured. AirSeal growth has lagged expectations, domestic orthopedics remains soft and higher working-capital and interest costs could limit near-term financial flexibility.

Image Source: Zacks Investment Research

CNMD’s Core Platforms Build Operating Momentum

Second-quarter revenues were $343.5 million, up 0.3% year over year. Excluding gastroenterology products tied to strategic exits, organic constant-currency revenues rose 6%, with international organic constant-currency growth reaching 9.9%.

AirSeal and Buffalo Filter supported General Surgery, while BioBrace contributed to Orthopedic Surgery growth. Stryker Corporation SYK, which operates across MedSurg and Orthopaedics, is a relevant peer as investors compare execution across surgical-device markets. Medtronic plc MDT, whose portfolio includes surgical robotics and surgical tools, provides another reference point for the broader procedural-technology backdrop.

CONMED’s Margin Gains Strengthen the Earnings Case

Reported gross margin expanded to 57.5% from 55% a year earlier. An $8.5 million tariff refund aided the quarter, but gross margin still improved 50 basis points excluding that benefit, indicating that mix, foreign exchange and operating execution also helped.

Adjusted EBITDA increased to $78.1 million and adjusted EBITDA margin improved to 22.7% from 20%. CONMED also raised its 2026 earnings guidance to $4.48-$4.60 per share from $4.30-$4.45, strengthening the earnings side of the recent stock move.

CONMED Corporation EPS Diluted (Quarterly)

CONMED Corporation eps-diluted | CONMED Corporation Quote

CNMD Still Faces Uneven Growth Signals

AirSeal sales improved sequentially and increased across both capital and single-use products, but growth remained below management’s expectations. CONMED expects improvement in the second half of 2026, though at a slower rate than previously assumed.

Direct smoke evacuation sales exceeded the company’s long-term high-single-digit to low-double-digit growth expectation, but original equipment manufacturer smoke demand declined modestly. Domestic orthopedic sales were nearly flat, even as international orthopedic revenues advanced 10.8% at constant currency.

CONMED’s Cash Flow Risks Could Test the Rally

Cash generation is a weaker part of the setup. Net cash provided by operating activities totaled $50.6 million for the first half of 2026, down from $70.7 million a year earlier, as inventory and working-capital requirements absorbed cash.

Management increased expected 2026 adjusted interest expense to about $33 million from $25-$27 million and lowered free cash flow guidance to about $115 million from roughly $125 million. Those pressures leave less room for execution slippage while CONMED continues funding growth initiatives.

CNMD’s Signals Point to a More Balanced Setup

The 16% monthly advance is supported by better organic growth, margin progress and higher earnings guidance, but the operating picture is not uniformly strong. AirSeal’s slower-than-expected pace, uneven domestic demand and softer cash conversion argue against treating the rally as a one-way signal.

CNMD currently carries a Zacks Rank #3 (Hold), along with a Value Score of A, Growth Score of C, Momentum Score of C and VGM Score of B. The Value Score points to relative valuation appeal, while the C grades for Growth and Momentum are more neutral. Likewise, Stryker and Medtronic also carry a Zacks Rank of 3. CNMD’s VGM Score of B is favorable on a blended basis, but with a Zacks Rank #3, the overall setup remains balanced rather than decisively bullish. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research